Corporate
2022.07.11
Lumosa Therapeutics is pleased to introduce our new CBO, Mr. Christopher Aleong
Corporate
2022.06.06
Lumosa's LT1001 approved by Malaysian DCA!
Corporate
2022.05.24
Lumosa Participating the 2022 BIO International Convention
Corporate
2022.03.25
Taiwan FDA Approved the Phase 2 IND for Multiple-dosing of LT3001
Corporate
2022.03.15
Lumosa to Attend Bio-Europe Spring
Corporate
2022.01.27
Lumosa to Present LT3001 at the International Stroke Conference 2022